Increasing Incidence of Cancer Leads to High Adoption of Biopsy Devices in US
Biopsy is a medical procedure involving extraction of sample cells/tissues from a tumor for examination and diagnosis of malignancy. The procedure is performed in two ways- needle-based minimally invasive procedures and open surgical procedures. Increasing incidence of cancer is has led to high adoption of these devices. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S.
Such scenario has thus led to approval and launch of new biopsy devices in the country. For instance, in December 2019, Medtronic plc received the U.S. Food and Drug Administration clearance for its Stealth Autoguide system, for biopsy procedures, stereoelectroencephalography (sEEG) depth electrode placement, and for the positioning of the Visualase bone anchor, which is used for catheter placement.
Currently, there are approximately 35 different types of devices available in the global biopsy devices market. This device field is expanding at a rapid pace due to the development of new techniques and the application of advanced technology. It will continue to impact the lives of thousands of individuals who take advantage of the convenience and value of these instruments every day. In the future, these innovations may benefit even those patients who undergo frequent or repeated biopsies.
Read more @ https://coherentmarketinsights-cmi.blogspot.com/2020/12/increasing-incidence-of-cancer-leads-to.html